Science 37, Inc. (SNCE)
|Net Income (ttm)||-46.21M|
|Day's Range||10.77 - 12.39|
|52-Week Range||8.42 - 15.10|
|Est. Earnings Date||n/a|
Science 37 Holdings, Inc. operates as a technology-enabled clinical trial company that engages in the development of networked patient-centric models for clinical research to accelerate biomedical discovery. The company develops NORA (Network Oriented Research Assistant), a cloud-based patient-centric mobile research platform that helps to offers end-to-end networked clinical trial services and allows researchers to communicate with patients and mobile nurses from homes using videos, photographs, and survey forms. It also offers Science 37 Meta... [Read more...]
In 2020, Science 37's revenue was $23.70 million, an increase of 68.34% compared to the previous year's $14.08 million. Losses were -$31.67 million, 71.5% more than in 2019.Financial Statements
Science 37 makes Nasdaq debut
Science37Nasdaq Clinical research company Science 37 CEO David Coman joins the Yahoo Finance's Adam Shapiro to discuss the company's SPAC debut. Don't Miss: Valley of Hype: The Culture That Built Elizab...
LifeSci Acquisition II Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Busi...
NEW YORK, June 16, 2021 (GLOBE NEWSWIRE) -- LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a blank check company formed for the purpose of pursuing targets that are focused on healthcare innovation, today...
Last week featured five announced SPAC deals and several rumors. The week also had earnings from several well-known former SPACs.
Science 37, a life science company, is tapping the craze of a special purpose acquisition company to help it with a major public listing. Specifically, its is penning a merger agreement with LifeSci Acq...
Science 37 to Become Publicly Listed via Merger with LifeSci Acquisition II Corp., Powering the Clinical Trial Operat...
LOS ANGELES & NEW YORK--(BUSINESS WIRE)-- #IPOs--Science 37, Inc. and LifeSci Acquisition II Corp announced that they have entered into a definitive business combination agreement.
NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) -- LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a blank check company targeting the biopharma sector, announced today that it priced its initial public offering ...